| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/11/2004 | US6733801 Method of using fermented glycine max (L) extract for enhancing natural killer cell activity |
| 05/11/2004 | US6733757 Adeno-associated virus capsid polypeptide for use as gene transfer tool in cell tranduction |
| 05/11/2004 | US6733755 Ligand for vascular endothelial growth factor receptor |
| 05/11/2004 | US6733743 Methods to impair hematologic cancer progenitor cells and compounds related thereto |
| 05/11/2004 | CA2312898C Long acting injectable formulations containing hydrogenated castor oil |
| 05/11/2004 | CA2104594C Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| 05/06/2004 | WO2004037857A1 Bfk protein as therapeutic molecules |
| 05/06/2004 | WO2004037817A1 N-oxide compounds |
| 05/06/2004 | WO2004037793A1 Pyrazole-4-alkanoate derivatives inhibiting cyclooxygenase and 5-lipoxygenase |
| 05/06/2004 | WO2004037288A1 Agent eleveting dendritic cell precursor level in blood |
| 05/06/2004 | WO2004037276A1 Method and composition for enhancing vascular function |
| 05/06/2004 | WO2004037258A1 A combination comprising combretastatin and anticancer agents |
| 05/06/2004 | WO2004037249A1 Agent for alleviation of functional disorder after cardiopulmonary resuscitation |
| 05/06/2004 | WO2004037246A1 Nerve fiber regeneration accelerator |
| 05/06/2004 | WO2004037187A2 Metal-containing materials, compositions and methods |
| 05/06/2004 | WO2004037184A2 Methods for the treatment of skin disorders |
| 05/06/2004 | WO2004037173A2 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | WO2004037171A2 Mitotic kinesin inhibitors |
| 05/06/2004 | WO2004031202A3 Condensed palatinose in hydrogenated form |
| 05/06/2004 | WO2004022537A3 Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands |
| 05/06/2004 | WO2004022041A3 Treatment of non-allergic rhinitis by means of selective phosphodiesterase-4 inhibitors |
| 05/06/2004 | WO2004018451A8 Pyridazinone-derivatives as pde4 inhibitors |
| 05/06/2004 | WO2004018044A3 N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent |
| 05/06/2004 | WO2004013629A3 Screening for agents suitable for treatment of leukocyte associated inflammatory diseases |
| 05/06/2004 | WO2004013119B1 The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
| 05/06/2004 | WO2004010950A3 Aryl substituted hydantoin compounds and their use as sodium channel blockers |
| 05/06/2004 | WO2004005281A8 Inhibitors of tyrosine kinases |
| 05/06/2004 | WO2004004750A3 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 05/06/2004 | WO2004002433A8 Synergistic interaction of abacavir and alovudine |
| 05/06/2004 | WO2004001068A3 Use of pp2a phosphatase modulators in the treatment of mental disorders |
| 05/06/2004 | WO2003105893A3 Probiotic therapies using lactobacillus reuteri |
| 05/06/2004 | WO2003105838A3 MODULATION OF ACTIVATION OF GLUCOCORTICOID RECEPTORS beta-BREAKDOWN PRODUCTS OF GLUCOCORTICOIDS |
| 05/06/2004 | WO2003105779A3 Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| 05/06/2004 | WO2003101376A3 Topical use of at least one double-stranded rna oligonucleotide (ds rna) |
| 05/06/2004 | WO2003097641A3 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases |
| 05/06/2004 | WO2003092580A3 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 05/06/2004 | WO2003090695A3 TREATMENT OF α-GALACTOSIDASE A DEFICIENCY |
| 05/06/2004 | WO2003082853A8 New compounds |
| 05/06/2004 | WO2003072801A3 Compositions and method for regulation of calcium-dependent signalling in brain |
| 05/06/2004 | WO2003051837A8 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr) |
| 05/06/2004 | WO2003040096A3 N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| 05/06/2004 | WO2003025019A9 Anti-pdgf antibodies and methods for producing engineered antibodies |
| 05/06/2004 | WO2003020219B1 Aerosolized decongestants for the treatment of sinusitis |
| 05/06/2004 | WO2003009817A9 Stable lyophilized pharmaceutical formulation of igg antibodies |
| 05/06/2004 | WO2003004467A3 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 05/06/2004 | WO2002102800A9 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| 05/06/2004 | WO2002096348A3 Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment |
| 05/06/2004 | WO2002089800A3 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 05/06/2004 | WO2002088078A3 INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES |
| 05/06/2004 | WO2002083240A9 Aromatase inhibition to enhance assisted reproduction |
| 05/06/2004 | WO2002057222A9 Thiol-based naaladase inhibitors |
| 05/06/2004 | WO2002020512A9 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
| 05/06/2004 | WO2001074296A3 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
| 05/06/2004 | US20040087801 Renin inhibitors; congesitive heart failure; glaucoma |
| 05/06/2004 | US20040087800 Spirooxindole derivatives are analgesics for the treatment of chronic pain. |
| 05/06/2004 | US20040087796 Substituted carbazoles as inhibitors of spla2 |
| 05/06/2004 | US20040087792 Tryptase-inhibitors |
| 05/06/2004 | US20040087791 Bis(substituted propynyl)-substituted benzenes, pyridines, pyrimidines, pyrazines, pyridines, furans and pyrroles; e.g., 3,5-bis-(3-(4-aminomethylbenzylaminocarbonyloxy)prop-1-ynyl)--1 -hydroxymethylbenzene |
| 05/06/2004 | US20040087784 Neuronal serine-threonine protein kinase |
| 05/06/2004 | US20040087778 Modified peptides as therapeutic agents |
| 05/06/2004 | US20040087657 Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
| 05/06/2004 | US20040087654 Nitric oxide synthase inhibitor phosphate salt |
| 05/06/2004 | US20040087652 Induction cell differentiation; apoptosis |
| 05/06/2004 | US20040087649 Cytotoxic agents comprising taxanes and their therapeutic use |
| 05/06/2004 | US20040087640 Administering by mouth; cyclooxygenase inhibitor; controlling particle size |
| 05/06/2004 | US20040087637 Antiserotonine agents; central nervous system disorders |
| 05/06/2004 | US20040087628 Enzyme inhibitors; antiarthritic agents; psoriasis; viricides; bactericides |
| 05/06/2004 | US20040087627 Decarboxylase inhibitors; cardiovascular diosrders; antidiabetic agents; anticancer agents; dietetics |
| 05/06/2004 | US20040087626 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase |
| 05/06/2004 | US20040087625 Dietetics; antilipemic agents; anticholesterol agents; reducing triglycerides |
| 05/06/2004 | US20040087624 Analgesics; antiinflammatory agents; immunology; bone disorders; neurodegradation diseases |
| 05/06/2004 | US20040087623 Pyrazole derivatives against tgf overexpression |
| 05/06/2004 | US20040087617 Asthma therapy; chronic obstructive pulmonary disease |
| 05/06/2004 | US20040087611 Cancer treatment by combination therapy |
| 05/06/2004 | US20040087607 Adjust intensity of analgesics; blocking gangliosides |
| 05/06/2004 | US20040087605 N-but-3-enyl norbuprenorphine and methods of use |
| 05/06/2004 | US20040087599 cGMP-PDE inhibitors for the treatment of erectile dysfunction |
| 05/06/2004 | US20040087597 Preventives and remedies for complications of diabetes |
| 05/06/2004 | US20040087595 1-aryl- or 1-alkylsulfony-heterocyclybenzazoles as 5-hydroxytryptamine-6 ligands |
| 05/06/2004 | US20040087590 Novel biphenyl and biphenyl-like cannabinoids |
| 05/06/2004 | US20040087588 Parp inhibitors |
| 05/06/2004 | US20040087585 Peptide deformylase inhibitors |
| 05/06/2004 | US20040087581 Heterocyclylalkylamines as muscarinic receptor antagonists |
| 05/06/2004 | US20040087574 Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient |
| 05/06/2004 | US20040087566 Enzyme inhibitors; anticancer agents |
| 05/06/2004 | US20040087552 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/06/2004 | US20040087538 Nucleic acids containing unmethylated cytosine-guanine dinucleotides activate lymphocytes and redirect an immune response from th2 to th1 |
| 05/06/2004 | US20040087535 Administering a nitric oxide synthase gene in the form of naked dna; angiogenesis inhibitors |
| 05/06/2004 | US20040087529 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 05/06/2004 | US20040087510 Cardiovascular diseases and disorders; sustained delivery of nitric oxide |
| 05/06/2004 | US20040087507 Containing amino acid; long term storage stability |
| 05/06/2004 | US20040087504 Novel peptide sy |
| 05/06/2004 | US20040087497 CD10-activated prodrug compounds |
| 05/06/2004 | US20040087487 Increasing concentration of dopamine neurotransmitter in central nervous system; using glycine-proline-glutamic acid (GPE); neural injury or disease |
| 05/06/2004 | US20040087486 Inhibiting vascular occlusive events; reducing circulating count below normal levels without serious adverse consequence |
| 05/06/2004 | US20040087484 Treating sexual dysfunction associated with hypertension; angiotensin receptor blocker with either antihypertensive agent or HMG-CoA reductase inhibitor |
| 05/06/2004 | US20040087035 Using myeloproliferative leukemic inhibitory agents to treatment and/ or prevention platelet related thrombotic and vaso-occlusive disorder |
| 05/06/2004 | US20040086982 Using transgenic bacillus to ferment vitamin b5, valine and isoleucine |
| 05/06/2004 | US20040086977 Fusion polypeptides of human serum albumin and a therapeutically active polypeptide |
| 05/06/2004 | US20040086976 Genetically engineered erythropoietin for diagnosis, prevention and treatment of thrombis, cancer, neovascularization, inflammation and autoimmune diseases |